Cyclerion Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cyclerion Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q3 2024.
  • Cyclerion Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2024 was $138K, a 13.2% decline year-over-year.
  • Cyclerion Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2024 was $606K, a 71% decline year-over-year.
  • Cyclerion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1.07M, a 82.9% decline from 2022.
  • Cyclerion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $6.25M, a 35% decline from 2021.
  • Cyclerion Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $9.61M, a 35.9% decline from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $606K $138K -$21K -13.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $627K $184K -$195K -51.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $822K $181K -$245K -57.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $1.07M $103K -$1.02M -90.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-05
Q3 2023 $2.09M $159K -$1.5M -90.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $3.59M $379K -$1.32M -77.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $4.91M $426K -$1.34M -75.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $6.25M $1.12M -$1.42M -55.9% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-05
Q3 2022 $7.68M $1.66M -$750K -31.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $8.43M $1.7M -$641K -27.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-28
Q1 2022 $9.07M $1.77M -$545K -23.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $9.61M $2.55M -$660K -20.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $10.3M $2.41M -$1.38M -36.5% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $11.7M $2.34M -$1.61M -40.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $13.3M $2.31M -$1.72M -42.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 $15M $3.21M -$1.26M -28.2% Oct 1, 2020 Dec 31, 2020 10-K 2022-02-24
Q3 2020 $16.3M $3.8M -$1.15M -23.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $17.4M $3.95M -$2.27M -36.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $19.7M $4.04M +$47K +1.18% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $19.6M $4.47M +$860K +23.8% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-25
Q3 2019 $18.8M $4.95M +$1.64M +49.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $17.1M $6.22M +$3.22M +107% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-03
Q1 2019 $13.9M $3.99M +$1.48M +59.1% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-04
Q4 2018 $12.4M $3.61M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $3.31M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $3.01M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-12
Q1 2018 $2.51M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.